News | January 03, 2024
WuXi XDC partners with IntoCell to accelerate ADC discovery and development
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent will supply sintilimab for the collaborated clinical trial
10+ emerging markets, Japan & ANZ transition in final phase
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated
